Compare BLKB & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | FTRE |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2004 | 2023 |
| Metric | BLKB | FTRE |
|---|---|---|
| Price | $31.38 | $17.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $50.00 | $14.06 |
| AVG Volume (30 Days) | 842.1K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $4.25 | $3.09 |
| P/E Ratio | $47.04 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $25.58 | $4.46 |
| 52 Week High | $74.86 | $18.67 |
| Indicator | BLKB | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 59.62 |
| Support Level | $28.88 | $15.40 |
| Resistance Level | $32.11 | $18.13 |
| Average True Range (ATR) | 1.45 | 0.88 |
| MACD | 0.41 | -0.06 |
| Stochastic Oscillator | 88.73 | 67.12 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.